References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21834 · 2024 · External reference

Unresolved reference

External reference

Long-term projections of cancer incidence and mortality in Japan and decomposition analysis of changes in cancer burden, 2020-2054: an empirical validation approach

10.3390/cancers14246076 · 2022 · External reference

10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer

10.1056/nejmoa1606220 · 2016 · External reference

Proton beam therapy in Japan: current and future status

10.1093/jjco/hyw102 · 2016 · External reference

Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer

10.1016/j.ijrobp.2007.07.2335 · 2008 · External reference

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

10.1016/s1470-2045(16)30102-4 · 2016 · External reference

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

10.1016/s1470-2045(14)70482-6 · 2015 · External reference

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial

10.1016/s1470-2045(15)00567-7 · 2016 · External reference

Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer

10.1200/jco.2016.71.7397 · 2017 · External reference

Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline

10.1016/j.prro.2018.08.002 · 2018 · External reference

Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial

10.1093/jrr/rrae026 · 2024 · External reference

Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer

10.1002/jmrs.551 · 2022 · External reference

A retrospective study of late adverse events in proton beam therapy for prostate cancer

10.3892/mco.2017.1372 · 2017 · External reference

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference

10.1016/j.ijrobp.2006.04.029 · 2006 · External reference

Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group

10.1002/cam4.1350 · 2018 · External reference

Proton therapy for localized prostate cancer: long-term results from a single-center experience

10.1016/j.ijrobp.2020.11.007 · 2021 · External reference

Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer

10.1007/s10147-017-1209-8 · 2018 · External reference

Long-term outcomes of a prospective study on highly hypofractionated intensity modulated radiation therapy for localized prostate cancer for 3 weeks

10.1016/j.prro.2023.06.004 · 2023 · External reference

Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study ``GUNMA0702''

10.1186/s12885-020-6570-8 · 2020 · External reference

Hypofractionated proton therapy in early prostate cancer: results of a phase I/II trial at Loma Linda University

10.14338/ijpt-19-00057 · 2019 · External reference

Argon plasma coagulation for rectal bleeding after prostate brachytherapy

10.1016/s0360-3016(01)01704-7 · 2001 · External reference

Risk factors of bleeding ulceration after argon plasma coagulation in patients with radiation-associated vascular ectasias

10.1016/j.gie.2025.07.001 · 2025 · External reference